MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Donevan, S. D.
Right arrow Articles by McCabe, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Donevan, S. D.
Right arrow Articles by McCabe, R. T.

Vol. 58, Issue 3, 614-623, September 2000

Conantokin G Is an NR2B-Selective Competitive Antagonist of N-Methyl-D-aspartate Receptors

Sean D. Donevan1 and R. Tyler McCabe

Department of Neurology, University of Utah (S.D.D.), and Cognetix, Inc. (R.T.M.), Salt Lake City, Utah

Conantokin G (Con G) is a 17-amino-acid peptide antagonist of N-methyl-D-aspartate (NMDA) receptors isolated from the venom of the marine cone snail, Conus geographus. The mechanism of action of Con G has not been well defined; both competitive and noncompetitive interactions with the NMDA-binding site have been proposed. In this study the mechanism of action and subunit selectivity of Con G was examined in whole-cell voltage-clamp recordings from cultured neurons and in two electrode voltage-clamp recordings from Xenopus oocytes expressing recombinant NMDA receptors. Con G was a potent and selective antagonist of NMDA-evoked currents in murine cortical neurons (IC50 = 480 nM). The slow onset of Con G block could be prevented by coapplication with high concentrations of NMDA or of the competitive antagonist (RS)-3-(2-carboxypiperazine-4-yl)-propyl-1-phosphonic acid. Furthermore, in oocytes expressing NR1a/NR2B receptors, Con G produced a rightward shift in the concentration-response curve for NMDA, providing support for a competitive interaction with the NMDA-binding site. Con G produced an apparent noncompetitive shift in the concentration-response curve for spermine potentiation of NMDA responses, but this was due to spermine-induced enhancement of Con G block. Spermine produced a similar enhancement of DL-2-amino-S-phosphopentanoic acid block. Finally, Con G selectively blocked NMDA receptors containing the NR2B subunit. These results demonstrate that Con G is a subunit-specific competitive antagonist of NMDA receptors. The unique subunit selectivity profile of Con G may explain its favorable in vivo profile compared with nonselective NMDA antagonists.


1 Current address: Parke-Davis Research, Ann Arbor, MI 48105.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
R. W. Teichert, E. C. Jimenez, V. Twede, M. Watkins, M. Hollmann, G. Bulaj, and B. M. Olivera
Novel Conantokins from Conus parius Venom Are Specific Antagonists of N-Methyl-D-aspartate Receptors
J. Biol. Chem., December 21, 2007; 282(51): 36905 - 36913.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
A. B. Alex, A. J. Baucum, and K. S. Wilcox
Effect of Conantokin G on NMDA Receptor-Mediated Spontaneous EPSCs in Cultured Cortical Neurons
J Neurophysiol, September 1, 2006; 96(3): 1084 - 1092.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. A. Waxman and D. R. Lynch
N-Methyl-D-aspartate Receptor Subtype Mediated Bidirectional Control of p38 Mitogen-activated Protein Kinase
J. Biol. Chem., August 12, 2005; 280(32): 29322 - 29333.
[Abstract] [Full Text] [PDF]


Home page
NeuroscientistHome page
E. A. Waxman and D. R. Lynch
N-methyl-D-aspartate Receptor Subtypes: Multiple Roles in Excitotoxicity and Neurological Disease
Neuroscientist, February 1, 2005; 11(1): 37 - 49.
[Abstract] [PDF]


Home page
J. Neurophysiol.Home page
L. Li, T. H. Murphy, M. R. Hayden, and L. A. Raymond
Enhanced Striatal NR2B-Containing N-Methyl-D-Aspartate Receptor-Mediated Synaptic Currents in a Mouse Model of Huntington Disease
J Neurophysiol, November 1, 2004; 92(5): 2738 - 2746.
[Abstract] [Full Text] [PDF]


Home page
J Child NeurolHome page
T. A. Simeone, R. M. Sanchez, and J. M. Rho
Molecular Biology and Ontogeny of Glutamate Receptors in the Mammalian Central Nervous System
J Child Neurol, May 1, 2004; 19(5): 343 - 360.
[Abstract] [PDF]


Home page
Physiol. Rev.Home page
H. TERLAU and B. M. OLIVERA
Conus Venoms: A Rich Source of Novel Ion Channel-Targeted Peptides
Physiol Rev, January 1, 2004; 84(1): 41 - 68.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. A. Hartings, M. L. Rolli, X.-C. M. Lu, and F. C. Tortella
Delayed Secondary Phase of Peri-Infarct Depolarizations after Focal Cerebral Ischemia: Relation to Infarct Growth and Neuroprotection
J. Neurosci., December 17, 2003; 23(37): 11602 - 11610.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
G. Kohr, V. Jensen, H. J. Koester, A. L. A. Mihaljevic, J. K. Utvik, A. Kvello, O. P. Ottersen, P. H. Seeburg, R. Sprengel, and O. Hvalby
Intracellular Domains of NMDA Receptor Subtypes Are Determinants for Long-Term Potentiation Induction
J. Neurosci., November 26, 2003; 23(34): 10791 - 10799.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. C. Klein, M. Prorok, Z. Galdzicki, and F. J. Castellino
The Amino Acid Residue at Sequence Position 5 in the Conantokin Peptides Partially Governs Subunit-selective Antagonism of Recombinant N-Methyl-D-aspartate Receptors
J. Biol. Chem., July 13, 2001; 276(29): 26860 - 26867.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics